Concepedia
Statistics
Publications
10
Citations
717
H-Index
Active since
2002
Affiliations
Almac (United Kingdom)(Current)
Novartis (Ireland)
Queen's University Belfast
Primary Children's Hospital
Boston Children's Hospital
Eamonn O’Brien is an author at Almac (United Kingdom) specializing in medicine, molecular oncology, and oncology.
Publications per year
2002–2023
Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
Richard D. Kennedy, Max Bylesjö, Peter Kerr et al. · Journal of Clinical Oncology · 2011 · 190 citations
Medicine, Oncology, Pathology +17
Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer
Jude M. Mulligan, Laura A. Hill, Steve Deharo et al. · JNCI Journal of the National Cancer Institute · 2014 · 124 citations · Full text
Medicine, Molecular Genetics, Oncology +17
Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.
Charlie Gourley, Andrena McCavigan, Timothy Perren et al. · Journal of Clinical Oncology · 2014 · 123 citations
Medicine, Oncology, Pharmacology +16
Val64Ile Polymorphism in the C-C Chemokine Receptor 2 Is Associated With Reduced Coronary Artery Calcification
Ana M. Valdes, Megan L. Wolfe, Eamonn O’Brien et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2002 · 79 citations
Medicine, Cardiology, Molecular Genetics +17
BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer
Judith Carser, Jennifer E. Quinn, Caroline O. Michie et al. · Gynecologic Oncology · 2011 · 64 citations
Medicine, Gynecology, Oncology +12
1–5 of 10